ASP Isotopes (NASDAQ:ASPI) Shares Down 4.1% - Should You Sell?

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) was down 4.1% during mid-day trading on Wednesday . The stock traded as low as $6.79 and last traded at $6.79. Approximately 296,838 shares were traded during trading, a decline of 90% from the average daily volume of 2,860,194 shares. The stock had previously closed at $7.08.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group upped their price objective on ASP Isotopes from $8.50 to $11.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st.

ASP Isotopes Price Performance

The company has a market capitalization of $631.16 million, a price-to-earnings ratio of -12.34 and a beta of 3.35. The company has a quick ratio of 7.17, a current ratio of 7.21 and a debt-to-equity ratio of 0.80. The company has a 50 day simple moving average of $7.43 and a 200 day simple moving average of $5.87.

Insider Activity

In other ASP Isotopes news, COO Robert Ainscow sold 66,668 shares of the company's stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $5.62, for a total transaction of $374,674.16. Following the completion of the sale, the chief operating officer directly owned 1,419,992 shares in the company, valued at $7,980,355.04. This represents a 4.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Paul Elliot Mann sold 316,666 shares of the company's stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $5.62, for a total value of $1,779,662.92. Following the sale, the chief executive officer owned 7,315,454 shares of the company's stock, valued at $41,112,851.48. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 766,667 shares of company stock valued at $4,358,502 over the last 90 days. 21.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ASP Isotopes

Several hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of ASP Isotopes by 9.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company's stock valued at $148,000 after buying an additional 2,709 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of ASP Isotopes by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 21,646 shares of the company's stock valued at $99,000 after buying an additional 2,757 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of ASP Isotopes by 56.3% during the 4th quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company's stock valued at $46,000 after buying an additional 3,682 shares during the period. SBI Securities Co. Ltd. raised its holdings in shares of ASP Isotopes by 84.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company's stock valued at $44,000 after buying an additional 4,299 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of ASP Isotopes by 8.2% during the 1st quarter. Rhumbline Advisers now owns 65,326 shares of the company's stock valued at $306,000 after buying an additional 4,963 shares during the period. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.